Overview

Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Determination of the effect of Neugranin on the duration and severity of severe neutropenia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries
Treatments:
Docetaxel
Doxorubicin
Lenograstim
Liposomal doxorubicin